The PrognosticRole of Tumor Marker CA-125 in B-Cell

AUTHORS

Bahram Memar 1 , Seyed Amir Aledavood 2 , * , Soodabeh Shahidsales 2 , Mitr Ahadi 3 , Mahdi Farzadnia 4 , Hamid Reza Raziee 2 , Sedighe Noori 5 , Naser Tayebi-Meybodi 4 , Sakineh Amouian 4 , Samira Mohtashami 2

1 Surgical Oncology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Cancer Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Dept. of Internal, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

4 Dept. of Pathology, Imam Reza Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

5 Medical Student, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

How to Cite: Memar B, Aledavood S A, Shahidsales S, Ahadi M, Farzadnia M, et al. The PrognosticRole of Tumor Marker CA-125 in B-Cell, Int J Cancer Manag. 2015 ; 8(1):e80580.

ARTICLE INFORMATION

International Journal of Cancer Management: 8 (1); e80580
Published Online: February 28, 2015
Article Type: Research Article
Received: May 01, 2014
Accepted: October 25, 2014

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: B-cell non-Hodgkin’s lymphoma (NHL) is a common malignancy of lymphoid tissues. Different types of NHL show various behaviors, prognoses, and responses to treatment. Evaluation of disease activity in NHL can be helpful in managing and even increasing the patient’s survey.

Methods and Results: In total, 121 patients (76 males and 45 females), and their age range were 18-53 years, were evaluated in this study. The mean level of serum carbohydrate antigen 125 (CA-125) was 89.3±18.5 u/ml, ranging from 27 to 135 u/ml. There were significant differences in International Prognostic Index (IPI) score (p=0.002), stage of the disease (p=0.006), mortality rate (p=0.02), and relapse rate (p=0.04) between patients with serum CA-125 level 35 u/ml.

Conclusion: CA-125 seems to be a useful and reliable tumor marker for monitoring a patient with NHL. It might be the time to consider CA-125 in staging, prognostic scoring, or decision making about NHL treatment.

Keywords

B cell non-Hodgkin’s lymphoma (NHL) tumor marker CA-125 mortality rate

© 2015, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

The Full text is available in PDF.

COMMENTS

LEAVE A COMMENT HERE: